Drug intelligence / Profile preview

OCT-648

Development stage: Preclinical
Lead developer: Oscotec
Modality: Small Molecules

Overview

OCT-648 is a novel drug candidate being developed by Oscotec Inc., a South Korean clinical-stage drug discovery company. It targets NUAK family kinase 1 (NUAK1), also known as AMPK-related protein kinase 5 (ARK5). While Oscotec is widely recognized for its oncology portfolio, OCT-648 is specifically positioned within the company's 'Next Generation Programs' for the treatment of cardiovascular diseases. The drug is currently in the preclinical stage of development, with clinical trials anticipated to commence in 2026. Oscotec focuses on the discovery of small molecules with novel mechanisms of action, suggesting that OCT-648 is a small molecule inhibitor designed to address unmet clinical needs in cardiovascular medicine.

Targets

NUAK1 (NUAK family SNF1-like kinase 1)

Beyond the preview

Go deeper on OCT-648.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OCT-648.

Explore the full profile